论文部分内容阅读
目的:探讨黛力新对脑卒中后抑郁患者临床症状及神经递质的影响。方法:将我院收治的94例脑卒中患者按照随机分层分组法分为观察组和对照组,对照组35例给予常规治疗,观察组59例早期介入抗焦虑药物治疗,观察两组治疗前后焦虑症状、神经功能、日常生活能力及神经递质变化。结果:观察组汉密尔顿焦虑量表(HAMA)评分及焦虑自评量表(SAS)评分均显著优于对照组(P<0.05),观察组神经功能缺损程度评分(NIHSS)及巴氏指数(BI指数)均显著优于对照组(P<0.05)。观察组血浆去甲肾上腺素(NE)、多巴胺(DA)及5-羟色胺(5-HT)含量均显著高于对照组,两组间差异有统计学意义(P<0.05)。结论:脑卒中患者早期介入抗焦虑药物治疗能显著改善焦虑症状,提高日常生活活动能力,对促进神经功能恢复有积极意义。
Objective: To investigate the effect of Deanxit on clinical symptoms and neurotransmitter in patients with post-stroke depression. Methods: 94 stroke patients admitted to our hospital were randomly divided into observation group and control group according to randomized stratified grouping method. 35 cases in control group were given routine treatment, and 59 cases in observation group were treated with anti-anxiety drugs at early stage. Anxiety, neurological function, daily living ability and neurotransmitter changes. Results: The HAMA scores and SAS scores in the observation group were significantly better than those in the control group (P <0.05). The scores of NIHSS and BI in the observation group Index) were significantly better than the control group (P <0.05). The levels of plasma norepinephrine, dopamine and 5-hydroxytryptamine in the observation group were significantly higher than those in the control group, with significant difference between the two groups (P <0.05). Conclusions: Early interventional anti-anxiety medication in patients with stroke can significantly improve the symptoms of anxiety and improve the activity of daily living, which is of positive significance to promote the recovery of neurological function.